Cargando…

S226. A STUDY COMPARING WEIGHT GAIN FROM ALKS 3831 TO OLANZAPINE IN EARLY-ILLNESS YOUNG ADULTS WITH SCHIZOPHRENIFORM, SCHIZOPHRENIA, OR BIPOLAR I DISORDER

BACKGROUND: Optimal pharmacological efficacy is crucial in first-episode and early-episode schizophrenia and bipolar I disorder. Olanzapine (OLZ) is a highly efficacious antipsychotic indicated for the treatment of schizophrenia and bipolar I disorder. However, the clinical utility of OLZ may be lim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simmons, Adam, McDonnell, David, Jiang, Ying, Graham, Christine, Silverman, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888899/ http://dx.doi.org/10.1093/schbul/sby018.1013

Ejemplares similares

F232. A PHASE 3 STUDY TO DETERMINE THE ANTIPSYCHOTIC EFFICACY AND SAFETY OF ALKS 3831 IN ADULT PATIENTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA
por: McDonnell, David, et al.
Publicado: (2018)

Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine‐Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study
por: Sun, Lei, et al.
Publicado: (2018)

Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder
por: Lipkovich, Ilya, et al.
Publicado: (2008)

Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder
por: Stauffer, Virginia L, et al.
Publicado: (2010)

Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis
por: Correll, Christoph U, et al.
Publicado: (2023)

An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder
por: Citrome, Leslie, et al.
Publicado: (2021)

Comment on “Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review”
por: Todtenkopf, Mark S., et al.
Publicado: (2023)

Hypocalcemia Masquerading as Schizophreniform Disorder
por: Mehta, Shivangi, et al.
Publicado: (2016)

Worth the Weight? Olanzapine Prescribing in Schizophrenia. A Review of Weight Gain and Other Cardiometabolic Side Effects of Olanzapine
por: Fitzgerald, Ita, et al.
Publicado: (2021)

Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers
por: Toledo, Frederico G. S., et al.
Publicado: (2021)

Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia
por: Tsuneyama, Nobuto, et al.
Publicado: (2016)

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
por: Citrome, Leslie, et al.
Publicado: (2019)

Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment
por: Grywińska, Weronika B., et al.
Publicado: (2023)

Do patients with schizophreniform and bipolar disorders show an intrathecal, polyspecific, antiviral immune response? A pilot study
por: Endres, Dominique, et al.
Publicado: (2017)

Weight gain with olanzapine: Drug, gender or age?
por: Jain, Sanjay, et al.
Publicado: (2006)

The Effect of Ranitidine on Olanzapine-Induced Weight Gain
por: Ranjbar, Fatemeh, et al.
Publicado: (2013)

HETEROGENEITY IN PLASMA HOMOVANILLIC ACID LEVELS IN SCHIZOPHRENIFORM DISORDER
por: Pradhan, N., et al.
Publicado: (1992)

Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review
por: Xue, Hai Bo Haber, et al.
Publicado: (2014)

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report
por: Okazaki, Kosuke, et al.
Publicado: (2017)

Metformin Attenuates Liver Fat Content: Finding from Schizophrenia Patients with Olanzapine-induced Weight Gain
por: Wang, Li, et al.
Publicado: (2020)

Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder
por: Doane, Michael J., et al.
Publicado: (2022)

Myoclonic Jerks and Schizophreniform Syndrome: Case Report and Literature Review
por: Endres, Dominique, et al.
Publicado: (2018)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
por: Ascher-Svanum, Haya, et al.
Publicado: (2014)

Review of olanzapine in the management of bipolar disorders
por: Narasimhan, Meera, et al.
Publicado: (2007)

Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients
por: Huang, Jing, et al.
Publicado: (2020)

A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection
por: Atkins, Susan, et al.
Publicado: (2014)

Metformin and Berberine Prevent Olanzapine-Induced Weight Gain in Rats
por: Hu, Yueshan, et al.
Publicado: (2014)

Corrigendum: Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients
por: Huang, Jing, et al.
Publicado: (2020)

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study
por: Katagiri, Hideaki, et al.
Publicado: (2013)

Olanzapine Discontinuation Emergent Recurrence in Bipolar Disorder
por: Arora, Manu, et al.
Publicado: (2014)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases
por: Detke, Holland C, et al.
Publicado: (2010)

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
por: Gao, Keming, et al.
Publicado: (2013)

Preventing Olanzapine-Induced Weight Gain Using Betahistine: A Study in a Rat Model with Chronic Olanzapine Treatment
por: Lian, Jiamei, et al.
Publicado: (2014)

The Antipsychotic Olanzapine Interacts with the Gut Microbiome to Cause Weight Gain in Mouse
por: Morgan, Andrew P., et al.
Publicado: (2014)

Olanzapine: Worsening of obsessive compulsive disorder and weight gain: case report
Publicado: (2022)

Longitudinal Gut Microbiota Dysbiosis Underlies Olanzapine-Induced Weight Gain
por: Qian, Li, et al.
Publicado: (2023)

Graves’ Thyrotoxicosis Presenting as Schizophreniform Psychosis: A Case Report and Literature Review
por: Ugwu, Ejiofor T., et al.
Publicado: (2016)

Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study
por: McDonnell, David P., et al.
Publicado: (2014)

Comparison of olanzapine-induced weight gain and metabolism abnormalities between topiramate and vitamin C in patients with schizophrenia: a preliminary study
por: Zhang, Jinling, et al.
Publicado: (2023)

Effects of socio‐demographic characteristics, premorbid functioning, and insight on duration of untreated psychosis in first‐episode schizophrenia or schizophreniform disorder in Northern Malawi
por: Kaminga, Atipatsa C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fp6t3onovt59n3kngo97giju2u